Cat. #162367
EN2 expressing Flp-In™ T-REx™ 293 cell line
Cat. #: 162367
Organism: Human
Tissue: Kidney
Disease: Salivary gland tumours
Model: Genetically modified cell line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Markku Varjosalo
Institute: University of Helsinki
Primary Citation: Kinnunen et al. (2023). Cancers (Basel). 15(17):4246. PMID: 37686522
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: EN2 expressing Flp-In™ T-REx™ 293 cell line
- Parental cell: Flp-In™ T-REx™ 293
- Organism: Human
- Tissue: Kidney
- Disease: Salivary gland tumours
- Model: Genetically modified cell line
- Description: Flp-In™ T-REx™ 293 cells expressing ETV6-NTRK3 (EN) variant 1 (EN2) oncofusion
- Biosafety level: 2
Handling
- Format: Frozen
- Growth medium: Low-glucose DMEM pH 7.4 supplemented with penicillin–streptomycin and 10% FBS
- Atmosphere: 5% CO2
- Shipping conditions: Dry ice
- Storage conditions: Liquid Nitrogen
- Cultured in antibiotics: Yes, penicillin/streptomycin
References
- Kinnunen et al. (2023). Cancers (Basel). 15(17):4246. PMID: 37686522
